AD 6626

Drug Profile

AD 6626

Alternative Names: AD-6626

Latest Information Update: 16 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer ALDEA Pharmaceuticals; Stanford University
  • Class Antianaemics; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alcoholism
  • Preclinical Fanconi's anaemia

Most Recent Events

  • 16 Jul 2015 ALDEA Pharmaceuticals plans a phase I trial in healthy volunteers in Australia (ACTRN12615000601538)
  • 20 Jan 2015 Phase-I clinical trials in Alcoholism in Australia (IV)
  • 18 Dec 2014 Clinical trials in Alcoholism (In volunteers) in Australia (IV) (ACTRN12614001333606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top